> Diabetes Research > C-Peptide Helps Curb Diabetic Neuropathy

C-Peptide Helps Curb Diabetic Neuropathy

A study revealed six-month treatment with bioactive C-peptide facilitates improvement in sensory nerve function among people with type 1 diabetes and those suffering from infant phase of diabetic neuropathy.

In order to test C-peptide’s efficacy in maintaining microvascular function, researchers studied 139 patients with type 1 diabetes who experience symptoms of diabetic neuropathy, specifically in lower extremeties. Through randomization, some participants had low dosage (1.5 mg) of C-peptide daily while others took thrice higher dosage. The remaining group was given placebo (sugar pill).

The research yielded positive results in favor of both low and high dose of C-peptide which showed those given this treatment had significantly reduced nerve and sensory conduction velocities at baseline. Researchers noted a 1 meter/second improvement in peak sensory nerve conduction velocity for both groups. But considerably higher cases of improvement, 37 percent, came from the C-peptide treatment team compared to control (placebo) group’s 19 percent.

Generally, patients given C-peptide treatment showed better improvement in neuropathy impairment assessment and vibration perception than those from the control group. During the course of study, C-peptide treatment group did not develop any side effects in relation to the drug, investigators noted.

According to head investigator Dr. Karin Ekberg, patients with type 1 diabetes may rely on C-peptide not only in terms of improving nerve function but also to relieve them from other complications related to diabetes. Ekberg’s team is aiming to pursue studies with higher number of patient population to further test C-peptide in terms of safety and effectively relieving patients of idabetic peripheral neuropathy.

“There are clinical and pre-clinical data to indicate that C-peptide administration serves to ameliorate both functional and structural abnormalities in type 1 diabetic neuropathy,” he was quoted as saying. He and his co-researchers strongly suggest that patients get c-peptide replacement during early stages of diabetes.

Related terms:

Related Posts:

» Tags: , , , ,

Related terms:

Leave a Reply

Your email address will not be published. Required fields are marked *